Disposition of 33941 shares by Sommadossi Jean-pierre of Atea Pharmaceuticals at 4.0458 subject to Rule 16b-3
| AVIR Stock | USD 2.95 0.01 0.34% |
Slightly above 55% of Atea Pharmaceuticals' investor base is interested to short. The analysis of overall sentiment of trading Atea Pharmaceuticals stock suggests that many investors are impartial at this time. Atea Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Atea Pharmaceuticals. Many technical investors use Atea Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Filed transaction by Atea Pharmaceuticals Director, Officer: President, Ceo, And Chairman. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Atea Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Atea Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Atea Pharmaceuticals Fundamental Analysis
We analyze Atea Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atea Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atea Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Atea Pharmaceuticals is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Atea Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Atea Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Atea Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Atea Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Atea Pharmaceuticals Related Equities
| ELEV | Elevation Oncology | 3.33 | ||||
| IMMX | Immix Biopharma | 1.02 | ||||
| CNSP | Cns Pharmaceuticals | 2.78 | ||||
| ENVB | Enveric Biosciences | 5.51 |
Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.